Angelika Riemer

Dr. Angelika Riemer is a leading researcher at the German Cancer Research Center (DKFZ) in Heidelberg and holds key leadership roles at the National Center for Tumor Diseases (NCT) and the German Center for Infection Research (DZIF). She serves as Co-Coordinator of the research area 'Infections of the Immunocompromised Host' at DZIF and leads the 'Immunotherapy' research structure at NCT Heidelberg. Since 2010, she has led independent research groups at DKFZ, achieving tenure in 2018, which elevated her junior group to a permanent division.

Her research focuses on immunotherapy, cancer immunology, and molecular vaccine design, particularly in the context of immunocompromised patients and tumor immune evasion. Her work bridges clinical dermatology and immunology with translational research, aiming to develop novel vaccines and immunotherapeutic strategies. She is deeply involved in national research consortia and has shaped strategic research directions in infection and cancer immunology.

Dr. Riemer has received numerous scientific awards, including the Ingrid zu Solms Science Award and recognition as a member of the Young Academy of Sciences, Germany. Her accolades reflect sustained excellence in interdisciplinary cancer research.

• Habilitation in Immunology, 2007
• Board-certified specialist in Immunology (2010) and Dermatology (2014)
• PhD and MD with highest honors (sub auspiciis praesidentis rei publicae), University of Vienna
• Postdoctoral training at Dana-Farber Cancer Institute, Harvard Medical School

She has mentored students and early-career researchers, though specific names are not listed in the provided text. Her leadership extends to grants and collaborative projects through DZIF and NCT, where she plays a strategic role in funding and research direction. She is also an elected member of the DKFZ Scientific Council since 2012.

Dr. Riemer is affiliated with major research structures including the Molecular Vaccine Design division at DKFZ, the Immunotherapy unit at NCT Heidelberg, and the DZIF partner site in Heidelberg, where she previously served as Deputy Speaker. These teams focus on translational immunology, vaccine development, and host-pathogen interactions in cancer patients.